share_log

Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $412,000.00 in Stock

Insider Buying: OPKO Health, Inc. (NASDAQ:OPK) CEO Acquires $412,000.00 in Stock

內部收購:Opko Health,Inc.(納斯達克代碼:OPK)首席執行官收購412,000.00美元股票
kopsource ·  2022/09/19 04:52

OPKO Health, Inc. (NASDAQ:OPK – Get Rating) CEO Phillip Md Et Al Frost purchased 200,000 shares of the firm's stock in a transaction dated Thursday, September 15th. The shares were bought at an average cost of $2.06 per share, with a total value of $412,000.00. Following the purchase, the chief executive officer now directly owns 197,456,694 shares of the company's stock, valued at approximately $406,760,789.64. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link.

奧普科健康公司(納斯達克代碼:OPK-GET Rating)首席執行官菲利普·馬德等·弗羅斯特在9月15日星期四的交易中購買了該公司20萬股股票。這些股票是以每股2.06美元的平均成本購買的,總價值為412,000.00美元。收購後,首席執行官現在直接擁有197,456,694股公司股票,價值約406,760,789.64美元。此次收購是在提交給美國證券交易委員會的一份法律文件中披露的,可以通過以下鏈接訪問該文件。

Phillip Md Et Al Frost also recently made the following trade(s):

菲利普·馬德和阿爾·弗羅斯特最近還進行了以下交易:

Get
到達
OPKO Health
Opko Health
alerts:
警報:
  • On Wednesday, August 17th, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.54 per share, for a total transaction of $508,000.00.
  • On Friday, August 5th, Phillip Md Et Al Frost acquired 350,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.29 per share, for a total transaction of $801,500.00.
  • On Tuesday, June 21st, Phillip Md Et Al Frost acquired 200,000 shares of OPKO Health stock. The shares were acquired at an average cost of $2.39 per share, for a total transaction of $478,000.00.
  • 8月17日,星期三,Phillip Md et Al Frost收購了OPKO Health的20萬股股票。這些股票是以每股2.54美元的平均成本收購的,總交易額為508,000.00美元。
  • 8月5日,星期五,Phillip Md et Al Frost收購了OPKO Health的350,000股股票。這些股票是以每股2.29美元的平均成本收購的,總交易額為801,500.00美元。
  • 6月21日,星期二,Phillip Md et Al Frost收購了OPKO Health的20萬股股票。這些股票是以每股2.39美元的平均成本收購的,總交易額為478,000.00美元。

OPKO Health Price Performance

Opko健康性價比

NASDAQ OPK opened at $2.05 on Monday. The firm's fifty day simple moving average is $2.42 and its two-hundred day simple moving average is $2.81. The company has a current ratio of 2.30, a quick ratio of 1.91 and a debt-to-equity ratio of 0.12. OPKO Health, Inc. has a 12-month low of $1.96 and a 12-month high of $5.25. The firm has a market capitalization of $1.58 billion, a P/E ratio of -7.07 and a beta of 1.75.

納斯達克OPK週一開盤報2.05美元。該公司的50日簡單移動均線切入位為2.42美元,200日簡單移動均線切入位為2.81美元。該公司的流動比率為2.30,速動比率為1.91,債務權益比率為0.12。Opko Health,Inc.的12個月低點為1.96美元,12個月高位為5.25美元。該公司的市值為15.8億美元,市盈率為-7.07,貝塔係數為1.75。

OPKO Health (NASDAQ:OPK – Get Rating) last released its quarterly earnings results on Thursday, August 4th. The biotechnology company reported ($0.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.02) by ($0.02). OPKO Health had a negative return on equity of 7.72% and a negative net margin of 14.18%. The firm had revenue of $309.90 million during the quarter, compared to analysts' expectations of $326.87 million. During the same period in the prior year, the firm posted ($0.03) earnings per share. OPKO Health's revenue for the quarter was down 30.0% compared to the same quarter last year. Analysts forecast that OPKO Health, Inc. will post -0.38 EPS for the current fiscal year.
奧普科健康(納斯達克代碼:OPK-GET Rating)最近一次發佈季度收益報告是在8月4日(星期四)。這家生物技術公司公佈了該季度每股收益(EPS)(0.04美元),低於(0.02美元)的普遍預期。Opko Health的股本回報率為負7.72%,淨利潤率為負14.18%。該公司本季度營收為3.099億美元,高於分析師預期的3.2687億美元。去年同期,該公司公佈的每股收益為0.03美元。與去年同期相比,Opko Health本季度的收入下降了30.0%。分析師預測,OPKO Health,Inc.本財年每股收益將為0.38美元。

Wall Street Analyst Weigh In

華爾街分析師也加入進來

Separately, Piper Sandler cut their price objective on shares of OPKO Health from $5.00 to $4.00 and set an "overweight" rating on the stock in a report on Friday, August 5th.

另外,派珀·桑德勒將OPKO Health的股票目標價從5.00美元下調至4.00美元,並在8月5日星期五的一份報告中對該股設定了“增持”評級。

Hedge Funds Weigh In On OPKO Health

對衝基金對OPKO健康的看法

Institutional investors and hedge funds have recently bought and sold shares of the company. Verition Fund Management LLC purchased a new stake in shares of OPKO Health during the second quarter valued at $36,000. Centiva Capital LP purchased a new stake in shares of OPKO Health during the second quarter valued at $131,000. Captrust Financial Advisors grew its holdings in shares of OPKO Health by 13.3% during the second quarter. Captrust Financial Advisors now owns 38,847 shares of the biotechnology company's stock valued at $98,000 after buying an additional 4,573 shares during the last quarter. Creative Planning grew its holdings in shares of OPKO Health by 4.6% during the second quarter. Creative Planning now owns 89,210 shares of the biotechnology company's stock valued at $226,000 after buying an additional 3,963 shares during the last quarter. Finally, Occudo Quantitative Strategies LP grew its holdings in shares of OPKO Health by 143.7% during the second quarter. Occudo Quantitative Strategies LP now owns 75,403 shares of the biotechnology company's stock valued at $191,000 after buying an additional 44,460 shares during the last quarter. 27.83% of the stock is owned by hedge funds and other institutional investors.

機構投資者和對衝基金最近買賣了該公司的股票。Verition Fund Management LLC在第二季度購買了OPKO Health的新股份,價值3.6萬美元。Centiva Capital LP在第二季度購買了OPKO Health的新股份,價值131,000美元。CapTrust Financial Advisors在第二季度增持了OPKO Health的股票13.3%。CapTrust Financial Advisors現在擁有這家生物技術公司38,847股股票,價值98,000美元,在上個季度又購買了4,573股。在第二季度,創意規劃公司持有的OPKO Health股票增加了4.6%。Creative Planning現在持有這家生物技術公司89,210股票,價值226,000美元,上個季度又購買了3,963股。最後,Occudo Quantity Strategy LP在第二季度增持了OPKO Health的股票143.7%。Occudo Quantity Strategy LP現在擁有這家生物技術公司75,403股票,價值19.1萬美元,在上個季度又購買了44,460股票。27.83%的股票由對衝基金和其他機構投資者持有。

About OPKO Health

關於OPKO健康

(Get Rating)

(獲取評級)

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers and governmental units; and a novel diagnostic instrument system to provide blood test results in the point-of-care setting, as well as 4Kscore prostate cancer testing services.

Opko Health,Inc.是一家醫療保健公司,在美國、愛爾蘭、智利、西班牙、以色列、墨西哥和國際上從事診斷和製藥業務。該公司的診斷部門經營着BioReference實驗室,該實驗室為疾病的檢測、診斷、評估、監測和治療提供實驗室測試服務,包括深奧測試、分子診斷、解剖病理學、遺傳學、婦女健康以及為醫生辦公室、診所、醫院、僱主和政府單位提供的矯正保健;以及在護理地點提供血液測試結果的新型診斷儀器系統,以及4KScore前列腺癌測試服務。

See Also

另請參閲

  • Get a free copy of the StockNews.com research report on OPKO Health (OPK)
  • Kroger's is Your One-Stop Consumer Staples Stock
  • Adobe Perfects the Art of the Faceplant for Investors
  • Tax Credits are the Incentives in the Inflation Reduction Act
  • Stock Market: 3 Islands Of Strength In A Sea Of Red
  • 3 Banks Worth Considering For Q4
  • 免費獲取StockNews.com關於OPKO健康的研究報告(OPK)
  • 克羅格百貨是你的一站式消費者史泰博股票
  • Adobe為投資者完善Facebook工廠的藝術
  • 税收抵免是《降低通貨膨脹法案》中的激勵措施
  • 股市:紅海中的三座強國
  • 第四季度值得考慮的3家銀行

Receive News & Ratings for OPKO Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OPKO Health and related companies with MarketBeat.com's FREE daily email newsletter.

接受OPKO健康日報的新聞和評級-在下面輸入您的電子郵件地址,通過MarketBeat.com的免費每日電子郵件時事通訊接收對OPKO Health和相關公司的最新新聞和分析師評級的每日簡要摘要。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論